BlackRock Capital Allocation Term Trust (NYSE:BCAT) Reaches New 1-Year High – Time to Buy?

BlackRock Capital Allocation Term Trust (NYSE:BCAT) hit a new 52-week high during trading on Tuesday . The company traded as high as $16.20 and last traded at $16.1650, with a volume of 150695 shares traded. The stock had previously closed at $16.08.

BlackRock Capital Allocation Term Trust Stock Up 0.2%

The company has a 50 day moving average of $15.76 and a two-hundred day moving average of $15.24.

BlackRock Capital Allocation Term Trust Announces Dividend

The business also recently disclosed a monthly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Tuesday, September 15th will be issued a dividend of $0.2542 per share. This represents a c) annualized dividend and a yield of 18.9%. The ex-dividend date of this dividend is Tuesday, September 15th.

Hedge Funds Weigh In On BlackRock Capital Allocation Term Trust

A number of hedge funds have recently made changes to their positions in the company. NewEdge Advisors LLC boosted its stake in shares of BlackRock Capital Allocation Term Trust by 4.7% in the third quarter. NewEdge Advisors LLC now owns 16,100 shares of the company’s stock worth $238,000 after acquiring an additional 724 shares during the last quarter. N.E.W. Advisory Services LLC boosted its stake in BlackRock Capital Allocation Term Trust by 100.0% during the 4th quarter. N.E.W. Advisory Services LLC now owns 2,400 shares of the company’s stock worth $34,000 after purchasing an additional 1,200 shares during the last quarter. Quantinno Capital Management LP grew its stake in BlackRock Capital Allocation Term Trust by 3.3% during the 1st quarter. Quantinno Capital Management LP now owns 41,232 shares of the company’s stock valued at $583,000 after acquiring an additional 1,324 shares in the last quarter. Walkner Condon Financial Advisors LLC grew its position in shares of BlackRock Capital Allocation Term Trust by 8.6% in the first quarter. Walkner Condon Financial Advisors LLC now owns 17,613 shares of the company’s stock valued at $249,000 after purchasing an additional 1,400 shares in the last quarter. Finally, Geneos Wealth Management Inc. lifted its position in BlackRock Capital Allocation Term Trust by 341.7% during the second quarter. Geneos Wealth Management Inc. now owns 2,045 shares of the company’s stock worth $31,000 after buying an additional 1,582 shares in the last quarter. Institutional investors and hedge funds own 36.12% of the company’s stock.

BlackRock Capital Allocation Term Trust Company Profile

BlackRock Capital Allocation Term Trust (NYSE: BCAT) is a closed-end, diversified management investment company organized as a term trust. The fund’s primary objective is to deliver high current income and total return by investing across a broad range of credit and equity markets. BCAT seeks to achieve this objective through a portfolio of corporate debt securities, floating-rate loans, convertible securities, common and preferred equity, and asset-backed securities.

BCAT employs an actively managed, multi-sector credit approach that spans investment-grade and below-investment-grade bonds, senior secured loans and structured credit.